Redeye updates its estimates and valuation following MedCap’s Q1 2026 report. Organic growth was 4%, a normal level for the company, which, together with 10% organic growth and FX changes, resulted in 13% total growth. The adj. EBITDA was SEK110m, a growth of 30%, thanks to a 3%-point margin expansion.
LÄS MER
